Project development plan

HpVac is developing the anti-allergy asset GBC-R1, for which it owns an exclusive license, and expects the preclinical candidate to enter IND-enabling studies in 2022. 


HpVac is aiming for a potential exit or co-development with a commercial partner either after obtaining IND status, or after a proof-of-concept (PoC) phase IIa clinical trial.


After successfully obtaining financing for its lead validation and lead optimization phases, HpVac will be seeking financing (CHF 5M) for the pre-IND studies in 2022.

Aim:

GMP production & stability, drug substance and documentation ready for clinical trial submission(s)

Duration:

12-18 months

Costs:

CHF 5 million

Funding:

starting soon

Aim:

identification of recombinant lead molecule, bioequivalence, mechanism of action

Duration:

approx. 12 month

Costs:

approx. CHF 1.5 Mio

Funding:

secured

Status:

completed

Aim:

optimized molecule ready for GMP production, stability tests and preclinical stage

Duration:

18-24 months (depending on the number of validation cycles required)

Costs:

CHF 750'000

Funding:

secured

Status:

ongoing

Opportunities

HpVac is currently open to industrial and/or financial partners to collaborate on the next phases of its pre-clinical development programme.

 

Financial partners will be able to rely on the HpVac's tested, solid expertise, based on over 20 years' experience in business and pharmaceutical development, and on the company's wide network of specialized consultants and CROs.

 

Interested parties are welcome to contact us on : hpvac@gbc-sa.com

Health market

The mode of action of GBC-R1 suggests that it could be deployed against several indications of the atopic march, e.g. atopic dermatitis, allergic asthma and allergic rhinitis, as well as other indications such as IBD or celiac disease.

 

The prevalence of all possible indications is on the rise; 5-year CAGR forecasts range from 2.8% (ulcerative colitis) to 9.7% (allergic rhinitis). The worldwide health costs caused by these indications together may exceed 55 Billion USD in 20231), while the pharmaceutical industry struggles to find affordable and effective alternatives to current standard treatments.

1) GlobalData Plc, 2018.